New medicines in the pipeline for Alzheimer's disease, osteoporosis, arthritis and Parkinson's disease are among the many promising treatments in development for diseases of aging, according to a new survey released by the Washington-based Pharmaceutical Research and Manufacturers of America.
New medicines in the pipeline for Alzheimer's disease, osteoporosis, arthritis and Parkinson's disease are among the many promising treatments in development for diseases of aging, according to a new survey released by the Washington-based Pharmaceutical Research and Manufacturers of America.
The latest survey highlights the work of 120 pharma and biotech companies:
•Â Forty-four drugs are in development for respiratory and lung disorders, the fourth leading cause of death among the elderly.
•Â Twenty-three are in development for diabetes, the sixth leading cause of death among people 65 and older.
•Â Twenty-one are in the pipeline for Alzheimer's disease, which will afflict 14 million Americans by mid-century unless a cure or method of prevention is found.
All of these potential medicines are in clinical trials or awaiting final approval by the Food and Drug Administration.
Said Alan F. Holmer, president of PhRMA, "Our aging populace underlines the need for prescription drug coverage for seniors, who expect and deserve access to the fruits of medical research. Medicare drug coverage must be crafted in a way that gives seniors access to the medicines of today and provides incentives for companies to discover the medicines of tomorrow." PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.